Thank you for your interest. Registration is now closed as these meetings have already taken place.
For additional learning in MS, please click here to participate in our enduring CE activity.

This series of regional continuing medical education (CME) activities is intended to provide education pertaining to the treatment
and management of multiple sclerosis.

This educational activity is designed for neurology clinicians, including physicians, nurse practitioners, PAs, and nurses who manage patients with multiple sclerosis.
After completing this activity, the participant will demonstrate the ability to:

  • Recognize and diagnose the spectrum of multiple sclerosis (MS), from clinically isolated syndrome (CIS) to the various forms of MS (relapsing-remitting and progressive forms), using established, updated clinical, imaging, and laboratory criteria
  • Appropriately use available and emerging disease modifying therapies (DMTs) for MS based on their efficacy, safety, and tolerability profiles, as well as their approved or anticipated indications for the various forms of MS
  • Recognize and manage treatment failure, including switching DMTs
  • Monitor disease and patient outcomes, including patient adherence, according to recommended protocols
  • Use shared decision making when prescribing DMTs to improve treatment adherence and patient outcomes

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

This activity is designated for 0.3 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

California Board of Registered Nursing

Provider is approved by the California Board of Registered Nursing, Provider Number 13485, for 1.0 contact hour.

How to Receive Credit

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within three weeks.

Patricia K. Coyle, MD, FAAN, FANA (Chair)
Professor & Vice Chair, Clinical Affairs
Department of Neurology
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, NY

James D. Bowen, MD
Medical Director, Multiple Sclerosis Center
Swedish Neuroscience Institute
Clinical Associate Professor, Neurology
University of Washington
Seattle, WA

Bruce A. Cohen, MD
Director, Multiple Sclerosis Program
Professor, Davee Department of Neurology
Feinberg School of Medicine
Northwestern University
Consultant Neurologist
Rehabilitation Institute of Chicago
Chicago, IL

John R. Corboy, MD
Professor and Vice Chair, Department of Neurology
Director, Neuroimmunology/MS Fellowship
University of Colorado School of Medicine
Aurora, CO

Stephen C. Krieger, MD, FAAN
Associate Professor, Neurology
Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai Hospital
New York, NY

Clyde E. Markowitz, MD
Director, Multiple Sclerosis Center
Associate Professor, Neurology
Hospital of the University of Pennsylvania
Philadelphia, PA

Harold Moses, Jr., MD
Associate Professor, Neurology
Neuroimmunology Division
Vanderbilt University Medical Center
Nashville, TN

Michael K. Racke, MD
Professor and Chair, Department of Neurology
Ohio State University College of Medicine
Columbus, OH

Andrew J. Solomon, MD
Associate Professor, Neurological Sciences
Division Chief, Multiple Sclerosis
Larner College of Medicine at The University of Vermont
Burlington, VT

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

40 minutes
Q&A Session
5 minutes
15 minutes

There is no fee for this educational activity.

If you would like more information about this educational initiative, please contact RMEI Medical Education, LLC via e-mail at

Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine. This activity is supported by educational grants from Biogen, Genentech, and Novartis Pharmaceuticals Corporation.

RMEI Medical Education, LLC's Privacy Policy

RMEI Medical Education, LLC is committed to protecting the privacy of patients, caregivers, healthcare professionals, and any others who register and/or participate in any medical education programming. RMEI does not sell, share, trade, or rent the personal identifying information of its users to third parties. RMEI collects no personal information about its users, except when specifically and knowingly provided by such users. A user's personal information may be used by RMEI to provide services to its participants.

RMEI may offer its users online surveys and questionnaires that ask users for opinions and/or other information. Such surveys are completed voluntarily. Any information submitted may be shared with other companies on an aggregate basis, but RMEI will not provide such companies with any information regarding the identity of any individual user.

Privacy of Children

RMEI does not knowingly collect personal identifying information from children younger than 13 years of age.

What Are "Cookies" and How Does RMEI Use Them?

A cookie is a string of characters stored in a text file that is sent to your hard drive where your Internet browser files are kept. Cookies enable websites to store small bits of information on your computer and retrieve that information at a later time.

RMEI uses temporary session cookies to facilitate your navigation through our websites. Session cookies are not permanently stored on your computer's hard drive. Rather, they are deleted when you log off our website.

RMEI uses persistent cookies for purposes such as accurately tracking the number of website users, remembering whether you have completed a survey/evaluation or have registered, and recalling certain customizations and preferences that you have specified. Persistent cookies are encoded so that the information they contain can be interpreted only by RMEI.

Please note that our cookies do not actually contain any personal identifying information. Thus your privacy is not affected. Visitors who are concerned about the use of cookies technology may opt to enable a feature in their browser technology that will erase cookies, block all cookies, or warn the user before cookies are stored or exchanged. However, please note that some parts of our website will not function or may be considerably slower if you do so.